Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipClinical responsibilities included:
Managerial Responsibilities
The RASP-UK initiative, or Refractory Asthma Stratification Programme, is a UK-based research effort designed to transform the management of severe asthma by adopting a more personalized treatment approach. Funded by the Medical Research Council (MRC), Asthma UK,and several pharmaceutical partners, the program received a combined investment of £9.6 million. It aims to address the significant unmet needs of patients with severe asthma who are poorly controlled on current therapies, accounting for nearly half of asthma-related healthcare costs in the UK.
Severe asthma often resists conventional treatments, which typically involve escalating doses of corticosteroids. RASP-UK focuses on two key objectives: identifying and supporting patients who struggle with medication adherence and developing tests to optimize corticosteroid use by evaluating biomarkers that predict treatment response. The program divides patients into subgroups, such as “T2-high” (responsive to corticosteroids) and “T2-low” (non-responsive), to facilitate more targeted therapy and to explore novel treatments for resistant cases.
Collaborating with UK universities, NHS severe asthma centers and industry partners, RASP-UK integrates advanced biomarker research and innovative treatment strategies. The initiative has already identified potential biomarkers for treatment response and developed methods for monitoring adherence via technology. The findings are expected to enable safer, tailored treatments, reduce side effects and open pathways for clinical trials of new drugs for severe asthma.
The initiative is recognized as a groundbreaking step toward precision medicine in asthma care, offering hope for improved outcomes and reduced disease burden for patients with severe asthma
Niche has been successfully managing the executive function of the RASP-UK consortium since the grant was awarded in 2014. The consortium consists of 13 clinical-academic centres, eight industry contributors and seven ancillary partners (organisations like Asthma UK) and is governed by an Executive Team. In serving RASP-UK, Niche provides regulatory, operational and oversight services in delivery of four separate work strands that currently incorporate seven clinical trials. Niche also works closely with patient groups through the RASP-UK patient input platform.